Intermediate Skeletal Muscle Cells occupy a significant place in the spectrum of muscle fiber types, standing between the fast-twitch (Type II) and slow-twitch (Type I) muscle fibers. These cells exhibit characteristics that share features of both fast and slow fibers, making them adaptable to various physiological demands. Intermediate fibers are characterized by a moderate contraction speed and a balance between endurance and strength capabilities. They contain a mix of myosin heavy chain isoforms, allowing for a more versatile performance. These cells are particularly prevalent in muscles that require a combination of endurance and strength, such as certain postural muscles. The metabolic profile of intermediate muscle cells falls between that of fast and slow fibers, relying on both aerobic and anaerobic pathways. The plasticity of these cells allows them to undergo transformation in response to specific stimuli, adapting to changes in workload or exercise patterns. This adaptability underscores the importance of intermediate muscle fibers in maintaining overall muscle function and performance. Understanding the characteristics and functions of these cells is vital for athletes, physiologists, and clinicians, as it provides insights into muscle physiology, training strategies, and the rehabilitation of muscle-related conditions.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy